EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HuR Confers Resistance of Hepatocellular Carcinoma to Lenvatinib by Inhibiting Ferroptosis

Siren Feng iD, Fang Wang, Huayi Wu, Xinran Lin, Xue Qi, Kun Liu iD, Qiushi Yin iD, Bo Lin iD, Mengsen Li iD, Mingyue Zhu iD

Journal of Cellular and Molecular Medicine · 2026-11 · 30 (21)

DOI: 10.1111/jcmm.71423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 03.11.2026. Verfasst von Siren Feng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Tropical Translational Medicine, Ministry of Education, Hainan Provincial Key Laboratory of Carcinogenesis and Intervention, School…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Ferroptosis, Quinolines, Liver Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the Joint Program on Health Science and Technology Innovation of Hainan Province, the Natural Science Foundation of Hainan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aim to explore whether human antigen R (HuR) inhibits ferroptosis confers resistance to lenvatinib in hepatocellular carcinoma (HCC). Bioinformatics analysis and immunofluorescence detection of 30 HCC tissue samples were used to verify the clinical correlation between HuR and glutathione peroxidase 4 (GPX4), establish a lenvatinib‐resistant HCC cell line, and evaluate the cell phenotypes and ferroptosis indicators (Fe 2+ , reactive oxygen species (ROS), lipid peroxidation, glutathione (GSH)) through functional experiments. The HuR‐GPX4 axis was analysed by genetic intervention methods and verified through xenograft mouse tumour models. Co‐expression of HuR/GPX4 in HCC tissues was associated with poor prognosis. Under lenvatinib treatment, the drug‐resistant cell lines showed increased malignant behaviour and ferroptosis resistance characteristics (decreased ferrous ions, ROS, lipid peroxidation, and increased GSH) in HCC cells, as well as upregulation of lenvatinib targeting vascular endothelial growth factor receptor 1 (VEGFR1)/fibroblast growth factor receptor 3 (FGFR3). HuR promotes the expression of GPX4 via cytoplasmic translocation. Interference with the expression of HuR could reverse the drug resistance phenotype and increase ferroptosis in lenvatinib‐induced HCC; overexpression of GPX4 partially restored drug resistance. HuR is an important molecule for conferring resistance to lenvatinib therapy and may be involved in inhibiting ferroptosis by upregulating the expression and activity of GPX4. This study provides a new strategy for targeting patients with HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularFerroptosisQuinolinesLiver NeoplasmsPhenylurea CompoundsDrug Resistance, NeoplasmELAV-Like Protein 1HumansAnimalsMiceGene Expression Regulation, NeoplasticCell Line, TumorPhospholipid Hydroperoxide Glutathione PeroxidaseReactive Oxygen SpeciesFemaleXenograft Model Antitumor AssaysMale

Stichwörter der Autor:innen

HuRdrug resistanceferroptosishepatocellular carcinomalenvatinib

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsELAV-Like Protein 1ELAVL1 protein, humanPhospholipid Hydroperoxide Glutathione PeroxidaseReactive Oxygen Species

Autor:innen und Institutionen

  • Key Laboratory of Tropical Translational Medicine, Ministry of Education, Hainan Provincial Key Laboratory of Carcinogenesis and Intervention, School of Basic Medical Sciences, Hainan Medical University, Haikou, Hainan…
  • Department of Medical Oncology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, P.R. China.

ORCID-Profile: Siren Feng, Kun Liu, Qiushi Yin, Bo Lin, Mengsen Li, Mingyue Zhu

Förderung

  • National Natural Science Foundation of China
  • the Joint Program on Health Science and Technology Innovation of Hainan Province
  • the Natural Science Foundation of Hainan Province
  • the Hainan Provincial Science and Technology Special Fund
  • Nanhai Junior Talent Program of Hainan Provincial Health Commission
  • Hainan Medical University Talent Launch Fund

Zitieren

APA

Feng, S., Wang, F., Wu, H., Lin, X., Qi, X., Liu, K., Yin, Q., Lin, B., Li, M., & Zhu, M. (2026). HuR Confers Resistance of Hepatocellular Carcinoma to Lenvatinib by Inhibiting Ferroptosis. Journal of Cellular and Molecular Medicine, 30(21). https://doi.org/10.1111/jcmm.71423

Vancouver

Feng S, Wang F, Wu H, Lin X, Qi X, Liu K, et al. HuR Confers Resistance of Hepatocellular Carcinoma to Lenvatinib by Inhibiting Ferroptosis. Journal of Cellular and Molecular Medicine. 2026;30(21). doi:10.1111/jcmm.71423

BibTeX
@article{Feng2026,
  author = {Feng, Siren and Wang, Fang and Wu, Huayi and Lin, Xinran and Qi, Xue and Liu, Kun and Yin, Qiushi and Lin, Bo and Li, Mengsen and Zhu, Mingyue},
  title = {HuR Confers Resistance of Hepatocellular Carcinoma to Lenvatinib by Inhibiting Ferroptosis},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {21},
  doi = {10.1111/jcmm.71423}
}
Kostenlos starten →